

Resource Summary Report

Generated by [RRID](#) on Jul 28, 2026

Rat Anti-CD44 Monoclonal Antibody, Allophycocyanin Conjugated, Clone IM7

RRID:AB_398661

Type: Antibody

Proper Citation

BD Biosciences Cat# 559250, RRID:AB_398661

Antibody Information

URL: http://antibodyregistry.org/AB_398661

Proper Citation: BD Biosciences Cat# 559250, RRID:AB_398661

Target Antigen: CD44

Host Organism: rat

Clonality: monoclonal

Comments: Applications: Flow cytometry

Antibody Name: Rat Anti-CD44 Monoclonal Antibody, Allophycocyanin Conjugated, Clone IM7

Description: This monoclonal targets CD44

Target Organism: mouse

Clone ID: IM7

Antibody ID: AB_398661

Vendor: BD Biosciences

Catalog Number: 559250

Record Creation Time: 20250820T064406+0000

Record Last Update: 20250821T004832+0000

Ratings and Alerts

No rating or validation information has been found for Rat Anti-CD44 Monoclonal Antibody, Allophycocyanin Conjugated, Clone IM7.

No alerts have been found for Rat Anti-CD44 Monoclonal Antibody, Allophycocyanin Conjugated, Clone IM7.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 31 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#).

Chen C, et al. (2026) B cells disrupt tertiary lymphoid structure formation and suppress anti-tumor immunity. *Cancer cell*.

Yang Z, et al. (2025) Temporally programmed STING nanoadjuvant delivery unlocks synergistic chemotherapy-induced antitumor immunity. *Science advances*, 11(29), eadw0797.

Yu H, et al. (2025) UDP-GlcUA triggers PKR kinase activity to promote liquid-liquid phase separation of TOP2A and enhances radioimmunotherapy resistance. *Molecular cell*, 85(21), 3913.

Verhagen MP, et al. (2024) The SW480 cell line as a model of resident and migrating colon cancer stem cells. *iScience*, 27(9), 110658.

Gonçalves MP, et al. (2024) A1-reprogrammed mesenchymal stromal cells prime potent antitumoral responses. *iScience*, 27(3), 109248.

Liu H, et al. (2023) Neutralizing IL-8 potentiates immune checkpoint blockade efficacy for glioma. *Cancer cell*, 41(4), 693.

Fukaya T, et al. (2023) Gut dysbiosis promotes the breakdown of oral tolerance mediated through dysfunction of mucosal dendritic cells. *Cell reports*, 42(5), 112431.

Du H, et al. (2023) Suppression of TREX1 deficiency-induced cellular senescence and interferonopathies by inhibition of DNA damage response. *iScience*, 26(7), 107090.

Pandey SP, et al. (2022) Tet2 deficiency drives liver microbiome dysbiosis triggering Tc1 cell autoimmune hepatitis. *Cell host & microbe*, 30(7), 1003.

Damasceno LEA, et al. (2022) STING is an intrinsic checkpoint inhibitor that restrains the TH17 cell pathogenic program. *Cell reports*, 39(8), 110838.

Miller CL, et al. (2022) Systemic delivery of a targeted synthetic immunostimulant transforms the immune landscape for effective tumor regression. *Cell chemical biology*,

29(3), 451.

Bikorimana JP, et al. (2022) Promoting antigen escape from dendritic cell endosomes potentiates anti-tumoral immunity. *Cell reports. Medicine*, 3(3), 100534.

Agliano F, et al. (2022) Nicotinamide breaks effector CD8 T cell responses by targeting mTOR signaling. *iScience*, 25(3), 103932.

Park JY, et al. (2022) In vivo availability of the cytokine IL-7 constrains the survival and homeostasis of peripheral iNKT cells. *Cell reports*, 38(2), 110219.

Lynn MA, et al. (2022) Protocol to colonize gnotobiotic mice in early life and assess the impact on early life immune programming. *STAR protocols*, 3(4), 101914.

Xu T, et al. (2022) Alternative splicing downstream of EMT enhances phenotypic plasticity and malignant behavior in colon cancer. *eLife*, 11.

Rustenhoven J, et al. (2021) Functional characterization of the dural sinuses as a neuroimmune interface. *Cell*, 184(4), 1000.

McLane LM, et al. (2021) Role of nuclear localization in the regulation and function of T-bet and Eomes in exhausted CD8 T cells. *Cell reports*, 35(6), 109120.

Giampazolias E, et al. (2021) Secreted gelsolin inhibits DNGR-1-dependent cross-presentation and cancer immunity. *Cell*, 184(15), 4016.

Nozais M, et al. (2021) MYC deficiency impairs the development of effector/memory T lymphocytes. *iScience*, 24(7), 102761.